Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016
Published Jul 30, 2016
85 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016, provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
- The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
- Identify the use of drugs for target identification and drug repurpo

  
Source:
Document ID
GMDHC0442TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview81
Therapeutics Development94
  Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Stage of Development91
  Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Therapy Area101
  Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Indication112
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Companies153
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Products under Development by Universities/Institutes182
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Therapeutics Assessment206
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action211
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Companies Involved in Therapeutics Development2614
  AbbVie Inc261
  Affibody AB271
  Anacor Pharmaceuticals, Inc.281
  Apexigen, Inc.291
  Cell Medica Limited301
  Handok Inc.311
  Immune Response BioPharma, Inc.321
  Novartis AG331
  Omnitura Therapeutics Inc.341
  Opsona Therapeutics Limited351
  Peptinov SAS361
  R-Pharm371
  Regeneron Pharmaceuticals Inc381
  TWi Pharmaceuticals, Inc.391
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Drug Profiles4027
  ABT-981 Drug Profile401
  AN-4161 Drug Profile411
  APX-002 Drug Profile421
  canakinumab Drug Profile435
  diacerein Drug Profile483
  DLX-2323 Drug Profile511
  DLX-2681 Drug Profile521
  HL-2351 Drug Profile531
  IR-1000 Drug Profile541
  IR-1002 Drug Profile551
  IR-888 Drug Profile561
  melittin Drug Profile571
  OMN-54 Drug Profile582
  PPV-01 Drug Profile601
  Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation Drug Profile611
  rilonacept Drug Profile623
  RPH-104 Drug Profile651
  Small Molecule Inflammasome Modulator Programme Drug Profile661
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Dormant Projects675
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Discontinued Products723
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Featured News &Press Releases759
  Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment751
  Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab751
  Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes761
  Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir761
  Mar 23, 2016: Turkish signature on the biomolecules study Hurriyet771
  Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients781
  Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting791
  Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes791
  Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia801
  Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan801
  Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China811
  Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan811
  Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States811
  Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States821
  Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States822
Appendix842
  Methodology841
  Coverage841
  Secondary Research841
  Primary Research841
  Expert Panel Validation841
  Contact Us841
  Disclaimer851

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-1-Beta-IL-1-Beta-or-Catabolin-or-IL1B-Pipeline-Review-H2-2016-2088-16339>
  
APA:
Global Markets Direct - Market Research. (2016). Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Interleukin-1-Beta-IL-1-Beta-or-Catabolin-or-IL1B-Pipeline-Review-H2-2016-2088-16339>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.